← Back to Clinical Trials
Recruiting NCT06814275

NCT06814275 Project neuroARTEMIS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06814275
Status Recruiting
Phase
Sponsor Wake Forest University Health Sciences
Condition Stimulant Use
Study Type INTERVENTIONAL
Enrollment 189 participants
Start Date 2025-04-29
Primary Completion 2028-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 59 Years
Study Type INTERVENTIONAL
Interventions
ARTEMISContingency management for Antiretroviral (ARV) adherence

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 189 participants in total. It began in 2025-04-29 with a primary completion date of 2028-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.

Eligibility Criteria

Inclusion Criteria: * 18-59 years old * Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) * Confirmed HIV diagnosis * Current receipt of daily oral antiretroviral therapy (ART) medication * English fluency/literacy Exclusion Criteria: * Acute brain infection (e.g., neurosyphilis, toxoplasmosis) * Acutely symptomatic bipolar I or psychotic disorder * Prescription for immunomodulatory medications or other immunotherapy * Any MRI contraindications * If applicable, on antidepressant medication regimen for at least 2 months

Contact & Investigator

Central Contact

Christina S Meade, PhD

✉ cmeade@wakehealth.edu

📞 336-716-0695

Principal Investigator

Christina S Meade, PhD

PRINCIPAL INVESTIGATOR

Wake Forest University Health Sciences

Frequently Asked Questions

Who can join the NCT06814275 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 59 Years, studying Stimulant Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06814275 currently recruiting?

Yes, NCT06814275 is actively recruiting participants. Contact the research team at cmeade@wakehealth.edu for enrollment information.

Where is the NCT06814275 trial being conducted?

This trial is being conducted at Winston-Salem, United States.

Who is sponsoring the NCT06814275 clinical trial?

NCT06814275 is sponsored by Wake Forest University Health Sciences. The principal investigator is Christina S Meade, PhD at Wake Forest University Health Sciences. The trial plans to enroll 189 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology